Guru P. Sonpavde, MD

Medical Oncology

Guru P. Sonpavde, MD

Guru P. Sonpavde, MD was the director of the bladder cancer program at Dana-Farber Cancer Institute and was on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus is on clinical trials to develop new drugs and combinations to treat urologic cancers, particularly bladder cancer. He also has led translational projects and developed prognostic classifications and endpoints focused on bladder cancer. He is a member of the Genitourinary Committee of Southwest Oncology Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.

View Profile

Related Videos

Bladder Cancer Research at ESMO Video

Bladder Cancer Research at ESMO

Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.

Bladder Cancer Advances Video

Bladder Cancer Advances

Dana-Farber's Guru Sonpavde, MD discusses two studies with promising results. One study looks at pre-operative therapy, the other study compares an antibody-drug conjugate to chemotherapy in urothelial carcinoma.

New Treatments for Bladder Cancer Patients Video

New Treatments for Bladder Cancer Patients

Bladder cancer therapies, once very limited, now offer more options to treat patients than ever before. Dana-Farber Cancer Institute's Bladder Cancer Director, Guru Sonpavde, MD, details new treatments and research initiatives on the horizon ...

Impact of Angiotensin Blockade on Response to PD1/L1 Inhibitors for Patients with Metastatic Urothelial Carcinoma (mUC) Video

Impact of Angiotensin Blockade on Response to PD1/L1 Inhibitors for Patients with Metastatic Urothelial Carcinoma (mUC)

Bladder cancer research presented by Dana-Farber's Guru Sonpavde, MD at ASCO #GU21: Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC) Abstract 453

Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC) Video

Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)

Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472

An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A) Video

An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)

Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429

Bladder Cancer Conference Highlights from ASCO 2022 Video

Bladder Cancer Conference Highlights from ASCO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2022.